期刊文献+

化疗前及中期PET/CT标准摄取值对淋巴瘤的预后价值 被引量:3

The Prognostic Value of Pre-therapy and Interim ^(18)F-FDG PET/CT Standard Uptake Value in Patients with Diffuse Large B-Cell Lymphoma
下载PDF
导出
摘要 目的:探讨化疗前及化疗中期^(18)F-FDG PET/CT显像SUV最大值(SUVmax)对弥漫大B细胞淋巴瘤(DLBCL)患者预后的价值。方法:37例病理证实的DLBCL患者,化疗前及2~4个疗程化疗后行PET/CT检查,计算Ki67与SUVmax的关系,按分期、国际预后指数(IPI)、疗效及复发与否分组,比较均值、计算最佳临界值并行生存分析。结果:①Ki67和SUVmax正相关(P=0.002)。②各组SUV0max无显著差异。③IV期、IPI高危组SUV2~4max高于其他组(P=0.015、0.007);复发组SUV2~4max高于未复发组,但无统计学差异;SUV2~4max最佳临界值为3.05,以该值分组的PFS无统计学差异。④IV期、IPI高危及复发组ASUVmax及ASUVmax%均较低(P=0.009、0.002、0.022),ASUVmax≤3.6和ASUVmax%≤44.9%者PFS较短,且后者差异更显著(P=0.028、0.006)。结论:SUVmax与Ki67正相关;△SUVmax和△SUVmax%的预后价值高于SUV2~4max,且以后者更佳。 Purpose: To discuss the the prognostic value of pre-therapy and interim 18F-FDG PET/CT SUVmax in patients with diffuse large B-cell lymphoma(DLBCL). Methods: Thirty-seven patients with pathologically confirmed DLBCL accepted PET/CT imaging before and after 2-4 courses of chemotherapy. The relevance between Ki67 and SUVmax was calculated. Cases were divided into different groups depending on staging, international prognostic index(IPI), therapy outcomes and relapse or not. Average values of groups were compared, and the Kaplan-Meier analysis of progression free survivals(PFS) based on optimum cutoffs calculated by ROC curve were undertaken. Results: 1. Positive correlation was revealed between Ki67 proliferative index and SUVmax (P=0.002). 2.There were no statistical differences of SUV0max between groups. 3. DLBCL patients with stage IV and high IPI revealed higher SUV2- 4max(P=O.O15 and 0.007 respectively); relapsers also showed higher SUV2-4max although the difference was of no significance(P=0.067), The optimum cutoff of SUV2-4max was 3.05, and bipartite groups based on this value took no significant difference in the aspect of PFS. 4.DLBCL patients with stage IV, high IPI, and relapse showed lower ASUVmax and ASUVmax% (P=0.009, 0.002 and 0.022 respectively). The optimum cutoffs were 3.6 and 44.9% respectively. The patients with A SUVmax~〈 3.6 and A SU'Vmax%~〈44.9% showed shorter PFS, and the latter one was of greater significance. Conclusion: Ki67 and SUVmax were positively correlated, A SUVmax and /x SUVmax% might be more valuable than SUV2-4max in prognosis of DLBCL patients, and ASUVmax% seemed to be better. SUV0max were unlikely to provide effective prognosticinformation.
出处 《中国医学计算机成像杂志》 CSCD 北大核心 2012年第4期355-359,共5页 Chinese Computed Medical Imaging
关键词 标准摄取值 淋巴瘤 弥漫大B细胞 体层摄影术 发射型计算机 Standard uptake value Lymphoma,diffused large B Cell Tomography, emission-computed
  • 相关文献

参考文献11

  • 1Michael P M, John F S, Rodney J H, et al. Overview of early response assessment in lymphoma with FDG-PET. Cancer image, 2007, 7: 10- 18.
  • 2Claude N, Lindi M W. Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors. Journal of Nuclear Medicine, 2008, 49:1804-1808.
  • 3高海燕,宋文忠,谢红军,刘浩,刘兆辉.PET/CT SUV_(max)值、核抗原Ki-67与淋巴瘤分期之间的相关性探讨[J].中国医学影像学杂志,2010,18(3):285-288. 被引量:8
  • 4Mitsuaki T, Hiroyuki S, Ichiro H, et al. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non- Hodgkin' s lyrnphoma: comparison with serum soluble interleukin-2 receptor values. The Japan Society of Clinical Oncology, 2009, 14: 150-158.
  • 5Weber WA. Monitoring tumor response to therapy with 18F-FLT PET imaging. Journal of Nuclear Medicine, 2010, 51:841-844.
  • 6Ngeow J Y Y, QuekR H H, Ng DCE, et al. High SUV uptake on FDG- PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Annals of Oncology, 2009, 20:1543-1547.
  • 7Ken H, Andreas K, Tibor S, et al. Predictive value of initial ~SF-FLT uptake in patients with aggressive non-hodgkin lymphoma receiving R-CHOP treatment. Journal of Nuclear Medicine, 2011, 52:690-696.
  • 8Hossein A, Margarida R, Rasoul Z, et al. Prognostic significance of the standardized uptake value of pre-therapeutic ~8F-FDG PET in patients with malignant lymphoma. Medical Oncology, 2010, 27: 1570-1576.
  • 9Andrea G, Martin H, Luigi R, et al. Early Interim 2-[18F]Fluoro-2- Deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin' s lymphoma: A report from a joint italian-Danish Study. Journal of Clinic Oncology, 2007, 25:3746-3752.
  • 10Emmanuel I, Chieh L, Jehan D, et al. Prognostic value of interim 18F- FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. Journal of Nuclear Medicine, 2009, 50:527-533.

二级参考文献16

  • 1Wang J,Sun NC,Nozama Y,et al.Histological and immunohisto-chemical characterization of extranodal diffuse large-cell lymphoma as with prominent spindle cell features.Histopathology,2001,39(5):476-481.
  • 2Kim SJ,Kim BS,Choi CW,et al.Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma,nasal type.Annals of Oncology,2007,18:1382-1387.
  • 3Szczuraszek K,Mazur G,Jelen M,et al.Prognostic Significance of Ki-67 Antigen Expression in Non-Hodgkin's Lymphomas.Anticancer Research,2008,28:1113-1118.
  • 4Kabickova E,Sumerauer D,Cumlivska E,et al.Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease.Eur J Nucl Med Mol Imaging,2006,33:1025-1031.
  • 5Christian la Fougère,Walter Hundt,Nicole Br?ckel,et a1.Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma[J].Eur J Nucl Med Mol Imaging,2006,33:1417-1425.
  • 6Lapela M,Leskinen S,Minn HRI,et al.Increased Glucose Metabolism in Untreated Non-Hodgkin's Lymphoma:A Study With Positron Emission Tomography and Fluorine-18-Fluorodeoxyglucose.Blood,1995,86(9):3522-2527.
  • 7Sachs S,Bilfinger TV,Komaraff E,Increased Standardized Uptake Value in the Primary Lesion Predicts Nodal or Distant Metastases at presentation in Lung Cancer.Clinical Lung Cancer,2005,6(5):310-313.
  • 8Patruno R,Zizzo N,Zito AF et al.Microvascular density and endothelial area correlate with Ki-67 proliferative rate in the canine non-Hodgkin's lymphoma spontaneous model.Leukemia Lymphoma,2006,47:1138-1143.
  • 9Scholzen T,Gerdes J.The Ki-67 protein:from the known and the unknown.J Cell Physiol,2000,182:311-322.
  • 10Broyde A,Boycov O,Strenov Y,et al.Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.American Journal of Hematology,2009,84:338-343.

共引文献7

同被引文献42

  • 1孙菁,周进祝.内科学[M].7版.北京:科学出版社,2003.
  • 2Haioun C, Itti E, Rahmouni A, et al. 18F fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) in aggres- sive lymphoma: an early prognostic tool for predicting patient outcome[J]. Blood, 2005, 106(4) : 1376-1381.
  • 3Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F- FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy[J]. J Nucl Med, 2009, 50(4):527-533.
  • 4Front D, Bar-Shalom R, Mor M, et al. Aggressive non-Hodgkin lymphoma:early prediction of outcome with 67Ga scintigraphy [J]. Radiology, 2000, 214(1):253-257.
  • 5Van Den Berg H, Verhulst L, Behrendt H, et al. Persistent mediasti-nal mass is not indicative of recurrence after chemo- therapy only in pae-diatric Hodgkins disease[J]. Br J Haema- tol, 2000, 109:104-108.
  • 6Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma E[J]. J Clin Oneol, 2007, 25 (5) : 579-586.
  • 7Griffeth LK, Dehdashti F, Mcguire AH, et al. PET evalua- tion of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D- glucose[J]. Radiology, 1992, 182(1) :185-194.
  • 8Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma[J]. Curr Opin Oncol, 2008, 20(2):206-219.
  • 9Yang DH, Min JJ, Jeong YY, et al. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and May im- pact on the therapeutic plans in patients with aggressive non- Hodgkin' s lymphoma [J]. Ann Hematol, 2009, 88 (5) : 425-432.
  • 10Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET[J]. J Nucl Med, 1991, 32(8) : 1508-1512.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部